|
| Section2 = | Section3 = }} Dexpramipexole (KNS-760704) is a drug that was investigated by Knopp Biosciences and Biogen Idec for the treatment of amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease. The drug failed to show efficacy in terms of function or survival in a Phase III study of patients with ALS.〔(【引用サイトリンク】url=http://www.biogenidec.com/PRESS_RELEASE_DETAILS.aspx?ID=5981&ReqId=1770780 )〕 In September 2009, dexpramipexole received Fast Track designation for ALS from the U.S. Food and Drug Administration (FDA).〔(FDA Fast Track KNS-760704 for ALS ), September 2, 2009〕 It has received Orphan Drug designation by both the FDA and the European Medicines Agency. Dexpramipexole is a low molecular weight, water-soluble, orally bioavailable, renally excreted compound with linear pharmacokinetics, and has been shown to be well tolerated in human subject testing.〔Safety, Tolerability, and Pharmacokinetics of KNS-760704 (Dexpramipexole) in Healthy Adult Subjects. Michael E. Bozik, James L. Mather, William G. Kramer, Valentin K. Gribkoff and Evan W. Ingersoll. J Clin Pharmacol. Published online 19 October 2010.〕 KNS-760704 is the enantiomer of pramipexole, and has been shown to improve mitochondrial function and to confer significant cellular protection in neurons under stress.〔KNS-760704 (6-benzothiazole-diamine dihydrochloride monohydrate ) for the Treatment of Amyotrophic Lateral Sclerosis. Valentin K. Gribkoff and Michael E. Bozik. CNS Neuroscience & Therapeutics 14 (2008) 215–226.〕 KNS-760704 was originally identified as a candidate therapy for ALS by James Bennett, M.D., Ph.D., then of the University of Virginia. A 2010 Phase II clinical trial involving 102 patients showed a slowing of ALS disease progression. In January 2013, Biogen Idec announced that it was discontinuing its development of dexpramipexole in ALS due to lack of efficacy in a Phase III study.〔 ==See also== * Pramipexole, the enantiomer of dexpramipexole 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「Dexpramipexole」の詳細全文を読む スポンサード リンク
|